#Sweden #Stockholm #Nevisense #SciBase #TO 2 Offer

SciBase's Offer to Repurchase Outstanding Warrants

SciBase Holding AB, a prominent player in medical technology, has recently made an announcement regarding its offer to repurchase all outstanding warrants of Series TO 2. The company officially disclosed this development on November 7, 2025, paving the way for strategic financial maneuvering. This initiative is part of a broader objective to enhance the company's financial structure and value for its shareholders.

Background of the TO 2 Offer

The decision to repurchase warrants is part of SciBase's strategic planning, aimed at optimizing its capital structure. The company has taken proactive steps to enhance shareholder value, thus reinforcing its commitment to a sustainable financial framework. This offer will commence on December 8, 2025, and will remain open until January 8, 2026. The expected announcement of the offer's outcome is set for January 9, 2026.

The information document associated with this offer has been duly registered with the Swedish Financial Supervisory Authority, making it accessible on SciBase's official website. Additionally, interested parties can find the document on the Bergs Securities website as well. This transparency is critical for investors looking for detailed information about the offer.

Importance of the Information Document

The release of the information document is a mandatory step as stipulated under the Regulation (EU) 2017/1129, ensuring that all potential and existing shareholders can make informed decisions regarding their investments. Additionally, the document is available in both Swedish and English, catering to a wider audience and minimizing language barriers. In case of any discrepancies between the two versions, the Swedish edition will take precedence.

In preparing the information document, SciBase adhered strictly to the legal requirements, ensuring that all necessary details are comprehensively presented. This document outlines the specifics of the TO 2 Offer, including the acceptance guidelines and the timeline of the transaction.

Financial Advisory and Support

To further bolster this process, SciBase has engaged Bergs Securities and Birchtree Advisory as financial advisors. Legal matters are being overseen by Advokatfirman Schjødt, ensuring that all legal frameworks are respected and adhered to throughout the offer's timeline. Such partnerships enhance SciBase's operational capacity and reassure investors of the offer's legitimacy.

About SciBase

SciBase is renowned for its role in dermatological advancements, particularly through its groundbreaking product, Nevisense. This technology employs artificial intelligence and advanced electrical impedance spectroscopy (EIS) to significantly improve diagnostic accuracy in skin health management. Founded on more than two decades of research at the Karolinska Institute, SciBase remains at the forefront of innovation within the medical technology landscape.

Committed to prioritizing patient welfare, SciBase's mission is clear— to reduce patient suffering and improve life quality through timely detection and intervention in dermatological diseases. The company achieved a milestone by listing on the Nasdaq First North Growth Market in June 2015, cementing its place as a key player in the medical technology sector.

Regulatory Considerations and Final Notes

As with any financial action, it is vital to consider the implications of regulatory restrictions pivoting on the nature of the TO 2 Offer. The company explicitly states that this release is not intended for distribution or publication in jurisdictions like the United States, Canada, or Australia, where additional regulations apply. Investors in these regions must ensure compliance with their local laws and seek the guidance of independent advisors for clarity on potential restrictions.

In summary, the repurchase of warrants by SciBase indicates a strategic maneuver targeting financial stability and shareholder value. As the offer kicks off in December, stakeholders should closely monitor developments and assess their positions accordingly. For continuous updates, investors are encouraged to visit SciBase’s official communication channels.